NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud's Syndrome With The FDA
Links shared publicly online about this topic.
- 1,158total visits
NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud's Syndrome With The FDA
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has granted the Company
View full resource at medicalnewstoday.com
Tags: Neurovascular Disorder, Raynaud Disease, Disease and Condition, Drug, FDA
Most Recently Shared on May 19, 2010 at 3:15 am By:
NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud's Syndrome With The FDA http://mnt.to/3CMb #regulatory
Also Shared By:
Advertisement
MNT Dermatology News
@mnt_dermatology
NexMed To Discuss P2/3 Protocol For NexACT(R)-Based Alprostadil Treatment For Raynaud's Syndrome With The FDA http://mnt.to/3CMb
1 year ago...